| 前收市價 | 5.40 |
| 開市 | 5.40 |
| 買盤 | 4.50 |
| 賣出價 | 7.20 |
| 拍板 | 47.50 |
| 到期日 | 2024-12-20 |
| 今日波幅 | 3.30 - 5.40 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 5 |
BenzingaFDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
On Friday, the FDA extended the target action date of priority review of supplemental application seeking approval for Dupixent (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD), a lung disease that’s usually caused by smoking. The revised target action date is September 27, 2024. The FDA accepted the application in February, with a target action date of June 27, 2024. The FDA did not raise any concerns regardi
ZacksFDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
Per the FDA, the data submitted by Sanofi (SNY)/Regeneron (REGN) for Dupixent in COPD indication constitutes a major amendment to its previously-submitted data. A final decision is expected by Sep 27.
ZacksPharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
J&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority Review tags to Sanofi's (SNY) and Roche's (RHHBY) regulatory applications.
